After receiving input from more than 80 institutions across the United States, the American Society of Health Systems Pharmacists (ASHP) and the American Pharmacists Association (APhA) developed a new medication management care transition guide.
After receiving input from more than 80 institutions across the United States, the American Society of Health Systems Pharmacists (ASHP) and the American Pharmacists Association (APhA) developed a new medication management care transition guide.
“Pharmacists’ leadership is integral to improving patient care throughout the entire medication-use process and all care settings. The programs highlighted in this report demonstrate how to improve medication adherence and reduce adverse drug events and hospital re-admissions,” said Paul W. Abramowitz, PharmD, CEO of ASHP.
The ASHP-APhA Medication Management in Care Transitions Best Practices identifies 8 programs that were distinguished as best practices because of their impacts of the care transitions model on patient care and pharmacist involvement in the transition process from inpatient to home settings. The 8 programs with the best transition programs include: Einstein Healthcare Network, Froedtert Hospital, Hennepin County Medical Center, Johns Hopkins Medicine, Mission Hospitals, Sharp HealthCare, the University of Utah Hospitals and Clinics, and the University of Pittsburgh School of Pharmacy and the University of Pittsburgh Medical Center.
The 8 organizations’ programs best demonstrate that patients benefit from the pharmacists’ medication expertise on care transitions teams. In addition, the successful transitions in these organizations depend on contributions by pharmacists, technicians, student pharmacists, supportive personnel, and other healthcare providers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
Read More
FDA Approves Stelara Biosimilar, Selarsdi
April 18th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Read More